Detection of Bacillus Galmette-Guerin (Mycobacterium bovis BCG) DNA in Urine Specimens after Intravesical BCG Immunotherapy for Non-muscle Invasive Bladder Cancer.

Detection of Bacillus Galmette-Guerin (Mycobacterium bovis BCG) DNA in Urine Specimens after Intravesical BCG Immunotherapy for Non-muscle Invasive Bladder Cancer. - BCG DNA study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012398

Enrollment

300

Registered

2013-12-10

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-muscle invasive bladder cancer after BCG intravesical instillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NMIBC (cTa or 1N0M0, pTa or 1 N0M0) after BCG intravesical instillation

Exclusion criteria

Exclusion criteria: urachal carcinoma

Design outcomes

Primary

Measure	Time frame
the presence or absence of urine BCG DNA The comparison in 5-year disease-specific survival between the presence and absence of urine BCG DNA	—

Countries

Japan

Contacts

Public ContactSATORU MUTO

Teikyo University, School of Medicine Department of Urology

muto@med.teikyo-u.ac.jp03-3964-1211

Outcome results